@article{456,
  author = {Amol Sura and Yuwei Sun and Amit Reddy and S Rathinam and John Gonzales and Radhika Thundikandy and Rajesh Vedhanayaki and Anuradha Kanakath and Bala Murugan and Thuy Doan and Lyndell Lim and Eric Suhler and Hassan Al-Dhibi and Nisha Acharya and FAST Group},
  title = {Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.},
  abstract = {<p><b>PURPOSE: </b>Some patients taking methotrexate (MTX) or mycophenolate mofetil (MMF) experience intolerable side effects at full doses. We evaluated whether dose reduction affected treatment outcomes in uveitis patients.</p>

<p><b>METHODS: </b>Subanalysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Patients were randomized to receive MTX (25 mg weekly) or MMF (3&nbsp;g daily). A pre-specified dose reduction protocol could be employed for intolerable side effects. Primary analysis was performed at 6&nbsp;months.</p>

<p><b>RESULTS: </b>43/194 patients (22%) required dose reduction. 88/151 patients (58%) on maximum doses and 32/43 patients (74%) on reduced doses were deemed treatment successes at 6 months. The odds ratio point estimate (1.60, 95% CI 0.72-3.74) favored dose-reduction but this was not significant. Following reduction, adverse events improved at the subsequent study visit (79 events reduced to 63 events).</p>

<p><b>CONCLUSION: </b>Dose reduction of antimetabolites was not associated with worse outcomes in this subanalysis of a uveitis trial.</p>
},
  year = {2023},
  journal = {Ocul Immunol Inflamm},
  pages = {1-6},
  month = {2023 Jan 26},
  issn = {1744-5078},
  doi = {10.1080/09273948.2023.2165949},
  language = {eng},
}